NVO
$38.45-0.14 (-0.35%)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabet...
Recent News
Why Eli Lilly Stock Just Dropped
Eli Lilly's stock price is based on growth rates that might fall short.
Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares
Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. The move adds to a rough stretch for the stock, which is now down 13% year to date from $1,072.90 at the start of 2026. The selloff reflects a convergence of pressures: mounting ... Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares
Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up.
Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.
This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.
Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss broadly comparable to Novo's own obesity pill, adding to a growing list of competitive threats facing the Danish pharmaceutical...